This site is intended for healthcare professionals

Eli Lilly reveals critical barriers to optimal migraine care and insights from novel clinical and patient-centric real-world evidence, supporting Lilly's preventive and acute treatment portfolio at AHS 2021.

Read time: 9 mins
Last updated:28th Jun 2021
Published:5th Jun 2021
To improve the understanding and advance the treatment of migraine, Eli Lilly and Company presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the American Headache Society (AHS) 2021 Virtual Annual Scientific Meeting, June 3-6 .
Condition: Migraine/Headache
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest